ArticleFrontiers in medicine2026
Deciphering molecular responses to radiofrequency microneedling in a 3D human skin model: new insights and modulation by aftercare treatment.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiofrequency microneedling (RFMN) is an emerging therapeutic approach that enhances skin rejuvenation by delivering targeted thermal injury to the dermal and subdermal layers while sparing the epidermis. However, the molecular mechanisms underlying its biological effects especially in comparison to medical microneedling remain poorly understood. In this study, we aimed to investigate, for the first time, the molecular and histological responses to RFMN using a standardized three-dimensional (3D) human skin model. As a secondary objective, we assessed the modulatory effects of RFMN aftercare treatment with a dexpanthenol-containing ointment. Methods: We investigated the molecular and histological responses to RFMN utilizing a previously established standardized human 3D skin model composed of primary dermal fibroblasts and epidermal keratinocytes. Histological assessments and transcriptomic analyses employing next-generation sequencing were conducted 48 and 120 h after RFMN treatment. In addition, the effects of a topical dexpanthenol-containing ointment administered immediately following RFMN on wound healing and gene regulation were evaluated. Results: Histological analysis of RFMN-treated 3D skin models showed dermal coagulation zones that disappeared after post-treatment with a dexpanthenol-containing ointment. Transcriptomic profiling 48 h after RFMN showed an early pro-inflammatory response with upregulated chemokines and cytokines (e.g., CCL7, CXCL2, IL24) and downregulated matrix metalloproteinases and barrier genes, indicating controlled inflammation and skin renewal initiation. Aftercare with the dexpanthenol-containing ointment elicited distinct gene expression changes at 120 h post-RFMN, including increased expression of cytokines (IL37), matrix metalloproteinases (MMP3, MMP8), and epidermal regeneration markers (LCE1B, VEGFA), consistent with accelerated wound healing, re-epithelialization, and inflammation modulation. Conclusion: In conclusion, this study elucidates the molecular and histological effects of RFMN and highlights the benefits of dexpanthenol-containing topical post-treatment, which may further shorten the already brief downtime. These findings support the optimization of clinical protocols for safer and more effective skin rejuvenation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.